Lung cancer is the second most common type of cancer in the U.S., accounting for more deaths than breast, prostate and colon cancer combined, according to the Centers for Disease Control and Prevention. Many people endure more than one type of lung cancer treatment, which can last for weeks to months.

Lead researcher Raimar Löbenberg and his colleagues Warren Finlay and Wilson Roa from the University of Alberta developed an inhalable dry powder using a common chemotherapy drug encapsulated into nanoparticles. Some mice were treated with the inhalable powder and others with the same drug through two different delivery methods, a solution and IV injection of drug bound nanoparticles.

Results showed that the inhalable dry powder was more effective than using the IV or solution. In the study, more than 80 percent of the mice survived for more than 90 days and more than 70 percent survived for 140 days. None of the mice treated with the IV injection or solution survived past 50 days.

"Current lung cancer treatments can be grueling and take a significant toll on the patient," said Löbenberg. "Our results show that this treatment method may not only increase someone's survival rate but could also potentially be less toxic to the body."

The inhalable dry powder was also more effective than the IV injection in reducing the amount and size of tumors. Large tumor masses were seen in the lungs of those animals that were not treated or treated with the IV injection or solution. Animals treated with the inhalable dry powder showed fewer and much smaller tumors.

Note: If no author is given, the source is cited instead.

• Lung Cancer
• Lung Disease
• Breast Cancer
• Diseases and Conditions
• Prostate Cancer
• Colon Cancer

• Nanomedicine
• Metastasis
• Tumor suppressor gene
• Lung cancer
• Glioma
• Carcinogen